FDA Classifies Convenience Kit Recalls Tied to BD ChloraPrep Applicator Contamination as Class I in October 2026: Entire Kits Must Be Destroyed

What Happened in October 2026

On October 14, 2026, the U.S. Food and Drug Administration (FDA) updated its communication page for the AVID Medical convenience kit recall, confirming that the action has been classified as a Class I recall — the most serious category used by the FDA. The product named is a non-sterile IV start kit (IV START KIT NON-STERILE, KIT) from AVID Medical, model AVID KIT KRIV26-02, kit lot 1658437, with Unique Device Identification (UDI) 10809160460481.

The FDA recorded the following timeline on the page: an Early Alert was issued on August 28, 2026, and the action was updated to a Class I recall on October 14, 2026.

Along the same chain, Medline's convenience kit recall page was updated as well. What the two actions have in common is that the kits contain ChloraPrep skin antiseptic applicators that BD has recalled.

The Source: BD's ChloraPrep Applicators

The chain begins with a nationwide recall issued by BD (Becton, Dickinson and Company) on June 6, 2026, and posted by the FDA on June 8, 2026. The recalled products are:

• ChloraPrep Clear 1 mL single sterile applicator — catalog number 930480, lot 4032183, NDC 54365-400-31
• FREPP Clear 1.5 mL paper-covered applicator — catalog number 930299, lot 4073005, NDC 54365-400-30

The reason for the recall is the potential for fungal contamination under specific environmental conditions, allowing growth of Aspergillus penicillioides. The affected lots were shipped to distributors and hospitals between March and June 2024.

BD stated that at that time it had received no reports of adverse events related to the recall, and noted that, in addition to the lots listed in the announcement, it had recalled other lots referenced in customer letters as a precautionary measure.

Risk Description

According to the official pages and the companies' risk statements, contamination of a skin antiseptic product with Aspergillus penicillioides may lead to serious consequences: systemic infection, sepsis, illness, and even death.

If the fungus enters a patient's bloodstream during insertion of a vascular catheter, the catheter may need to be removed and the patient may require a second procedure. If it causes a surgical site infection, medical and surgical intervention may be required, along with long-term antifungal therapy.

These statements appear consistently in the BD announcement and on the AVID Medical and Medline recall pages.

Escalation from a Single Component to the Entire Kit

The key change in this update is the disposition requirement. In its notice of July 22, 2026, AVID Medical required affected convenience kits to be over-labeled with instructions telling users to remove and discard the affected component before use.

By its customer letter of August 20, 2026, the requirement was escalated to: destroy the entire convenience kit directly, rather than removing just one item from it.

Medline's path was similar: on June 12, 2026 it initially required over-labeling, and on August 11, 2026 it changed to destroying the entire kit.

The FDA notes on its page that these kits had previously been identified as part of the recall, and that legacy labels stating "discard the affected component at time of use" may still remain in the field. Those products must be re-handled in accordance with the latest requirement; the old label's disposition logic cannot be followed.

Why the Downstream Impact Is Amplified

Convenience kits do not manufacture the antiseptic themselves; they assemble multiple consumable and drug components into a single surgical or procedural kit. When one applicator lot fails upstream, the problem propagates through the assembly step into multiple kit models, multiple distributors, and multiple clinical departments.

This has the same structural pattern as the earlier downstream corrections triggered by the saline ampoule chain: the true origin lies at the component supply level, while the recall appears at the clinical level in the form of "kits" and "trays."

For companies and healthcare institutions, determining whether they are affected cannot rely solely on the kit's own lot number — it must trace back to the sources of the components inside the kit.

Identification and Self-Check Points

Several actionable points can be drawn from the public information:

• Cross-check inventory against the AVID Medical and Medline affected lists to determine whether any kits contain a ChloraPrep Clear 1 mL (lot 4032183) or FREPP Clear 1.5 mL (lot 4073005) component.
• Do not treat prior over-labeling as evidence that disposition has been completed — the current requirement is to destroy the entire kit.
• Distributors that have already resold or transferred product must notify downstream customers and recover the quantities involved.
• Complete the response form before destruction, and return quantity and distribution information as required.

Sources and Scope of Verification

Sources:

• U.S. Food and Drug Administration (FDA) — Convenience Kit Recall: AVID Medical Removes Convenience Kits Affected by BD ChloraPrep Applicator Recall (page updated on October 14, 2026, confirming Class I Recall classification and recording the Early Alert of August 28, 2026).
• U.S. Food and Drug Administration (FDA) — Convenience Kit Recall: Medline Removes Convenience Kits Affected by BD ChloraPrep Applicator Recall.
• U.S. Food and Drug Administration (FDA) — BD Issues Nationwide Recall for Specific Lots of ChloraPrep Clear Single Sterile 1 mL and FREPP Clear 1.5 mL Applicators Due to Microbial Contamination (company announcement dated June 6, 2026; FDA posting date June 8, 2026).

Links:

• https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/convenience-kit-recall-avid-medical-removes-convenience-kits-affected-bd-chloraprep-applicator-0
• https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/convenience-kit-recall-medline-removes-convenience-kits-affected-bd-chloraprep-applicator-recall
• https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/bd-issues-nationwide-recall-specific-lots-chlorapreptm-clear-single-sterile-1-ml-and-frepptm-clear

Verification scope and access date: This verification was conducted on October 15, 2026, accessing the FDA official pages listed above to confirm the reason for the recall, the affected models and lots, the timing of changes to the disposition requirements, and the date of the Class I recall classification. No company or product information beyond the official pages has been added.

Applicability statement: This article is an interpretation of publicly available regulatory information. It does not constitute a conclusion or commitment regarding any specific product, company, or registration application, nor does it represent a regulatory authority's determination regarding any company's product. The official texts govern in all respects, and the information may change with subsequent official updates.

AIMEILI Regulatory Interpretation

This case illustrates a well-established pattern in FDA enforcement that is frequently underestimated by manufacturers: a component-level recall can escalate into a Class I recall at the finished-kit level, even when the kit assembler is not the party that caused the defect. Class I is reserved for situations in which there is a reasonable probability that use of the device will cause serious adverse health consequences or death. The FDA's willingness to apply it here reflects the severity of the organism involved and the difficulty of controlling exposure once a contaminated applicator is packaged inside a sterile-field kit.

Three regulatory mechanics are worth noting:

• Recall classification is based on the finished device as distributed, not on the failing component alone. A convenience kit is a device in its own right; it carries its own UDI, listing, and recall obligations. The kit manufacturer or contract assembler remains the recalling firm for the kit, regardless of who supplied the defective component.
• Correction strategies can be escalated by the agency mid-recall. Over-labeling is a legitimate correction strategy only where it reliably prevents exposure. Where the agency concludes that field-level removal of a component cannot be guaranteed, the acceptable correction becomes product destruction. Firms that treat the original correction letter as the final word risk being out of compliance with the updated requirement.
• Supply-chain traceability is the operative control. Identifying affected inventory requires component-level lot traceability (ChloraPrep Clear 1 mL lot 4032183 and FREPP Clear 1.5 mL lot 4073005), not just kit-level lot screening.

For regulatory affairs teams, the practical implications are that supplier qualification, change control, and incoming component lot tracking must be designed to support a rapid, component-level recall query across all finished kit configurations in which the component is used — including customer-specified configurations.

Business Impact

• Scope expansion across kit models and customers. A single applicator lot can be present in many kit configurations distributed to many hospitals and integrated delivery networks. The Class I reclassification will drive expanded customer notifications, broader field action volumes, and longer remediation timelines than the original component recall suggested.
• Full-kit destruction changes the cost structure. Destroying entire kits rather than removing one component increases write-offs by an order of magnitude relative to component-level replacement, and it removes the option of salvaging unaffected kit contents. Firms should model this cost and reflect it in recall reserve assumptions.
• Legacy over-labels create residual liability. Any product still bearing the older "discard the affected component at time of use" instruction must be re-handled. Distributors and clinical end users holding such stock should not treat the prior labeling as evidence of compliance.
• Reporting and documentation obligations intensify. Class I recalls typically require more frequent status reporting to the FDA, documented effectiveness checks, and clear evidence that consignees have received and acted on the notification. Response forms, quantities destroyed, and distribution tracing should be completed before destruction is carried out.
• Commercial and procurement consequences for suppliers and assemblers. Kit assemblers named in the action face increased scrutiny in supplier audits and in hospital value-analysis committee reviews. Expect customers to demand component-level traceability data and contractual recall-indemnification terms that expressly address upstream component defects.